As shown in Fig. 3, temozolomide (TMZ), the most common chemotherapeutic agent in GBM therapy, increased Akirin-2 and Twist-1 expression [for Twist-1 data are in accordance with our previously performed ones (Kubelt et al., in press [18])]. This evidence concerns the gene AKIRIN2 and glioblastoma.